171 related articles for article (PubMed ID: 33668932)
21. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.
Hickey RM; Kulik LM; Nimeiri H; Kalyan A; Kircher S; Desai K; Riaz A; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2017 Nov; 28(11):1487-1494. PubMed ID: 28912090
[TBL] [Abstract][Full Text] [Related]
22. High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity.
Ringel-Scaia VM; Beitel-White N; Lorenzo MF; Brock RM; Huie KE; Coutermarsh-Ott S; Eden K; McDaniel DK; Verbridge SS; Rossmeisl JH; Oestreich KJ; Davalos RV; Allen IC
EBioMedicine; 2019 Jun; 44():112-125. PubMed ID: 31130474
[TBL] [Abstract][Full Text] [Related]
23. InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity.
Zhou F; Li X; Naylor MF; Hode T; Nordquist RE; Alleruzzo L; Raker J; Lam SS; Du N; Shi L; Wang X; Chen WR
Cancer Lett; 2015 Apr; 359(2):169-77. PubMed ID: 25633839
[TBL] [Abstract][Full Text] [Related]
24. Cancer vaccines.
Butterfield LH
BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
[TBL] [Abstract][Full Text] [Related]
25. Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy.
Luo M; Shao B; Nie W; Wei XW; Li YL; Wang BL; He ZY; Liang X; Ye TH; Wei YQ
Sci Rep; 2015 Jun; 5():11062. PubMed ID: 26098663
[TBL] [Abstract][Full Text] [Related]
26. Glycated chitosan as a new non-toxic immunological stimulant.
Song S; Zhou F; Nordquist RE; Carubelli R; Liu H; Chen WR
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):202-8. PubMed ID: 19514994
[TBL] [Abstract][Full Text] [Related]
27. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats.
Chen WR; Liu H; Ritchey JW; Bartels KE; Lucroy MD; Nordquist RE
Cancer Res; 2002 Aug; 62(15):4295-9. PubMed ID: 12154032
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
29. Thermal ablation and immunomodulation: From preclinical experiments to clinical trials.
Takaki H; Cornelis F; Kako Y; Kobayashi K; Kamikonya N; Yamakado K
Diagn Interv Imaging; 2017 Sep; 98(9):651-659. PubMed ID: 28579522
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Butt AQ; Mills KH
Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
[TBL] [Abstract][Full Text] [Related]
31. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
32. Local tumour ablative therapies: opportunities for maximising immune engagement and activation.
O'Brien MA; Power DG; Clover AJ; Bird B; Soden DM; Forde PF
Biochim Biophys Acta; 2014 Dec; 1846(2):510-23. PubMed ID: 25286319
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral Immunotherapy and Tumor Ablation: A Local Approach with Broad Potential.
Senders ZJ; Martin RCG
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406525
[TBL] [Abstract][Full Text] [Related]
34. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
35. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
36. N-dihydrogalactochitosan-supported tumor control by photothermal therapy and photothermal therapy-generated vaccine.
Korbelik M; Banáth J; Zhang W; Hode T; Lam SSK; Gallagher P; Zhao J; Zeng H; Chen WR
J Photochem Photobiol B; 2020 Mar; 204():111780. PubMed ID: 31981988
[TBL] [Abstract][Full Text] [Related]
37. The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules.
Keisari Y; Kelson I
Cells; 2021 Jan; 10(2):. PubMed ID: 33503958
[TBL] [Abstract][Full Text] [Related]
38. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy.
Jiang L; Wang YJ; Zhao J; Uehara M; Hou Q; Kasinath V; Ichimura T; Banouni N; Dai L; Li X; Greiner DL; Shultz LD; Zhang X; Sun ZJ; Curtin I; Vangos NE; Yeoh ZC; Geffken EA; Seo HS; Liu ZX; Heffron GJ; Shah K; Dhe-Paganon S; Abdi R
Cell; 2020 Nov; 183(5):1219-1233.e18. PubMed ID: 33242418
[TBL] [Abstract][Full Text] [Related]
39. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
[TBL] [Abstract][Full Text] [Related]
40. Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity.
Mashino K; Sadanaga N; Tanaka F; Ohta M; Yamaguchi H; Mori M
Mol Cancer Ther; 2002 Aug; 1(10):785-94. PubMed ID: 12492111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
